Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEEP-ON: Lokelma vs Standard of Care for Hyperkalemia in CKD
NCT06578533Phase 3Recruiting
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Sep 2022
- Primary completion
- Jul 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium zirconium cyclosilicate in hyperkalemia (2 arms), sponsored by INCLIVA Biomedical Research Institute. Primary endpoint: Percentage of patients achieving serum potassium < 5.5 mEq/L at three or all timepoints at 90 days. Started Sep 2022; status: recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT06578533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578533.